Asset profile
MGD014
Multispecific antibody
Evidence outlook · lead readout
NCT03570918 · HIV-1-infection
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT03570918: Every participant in this trial knowingly received MGD014, with doses stepped up across small groups and no placebo or blinding, so there is no built-in comparison to separate the drug's effects from chance or natural variation. The results that are posted are limited to side-effect counts in each small dose group, with no measure of whether the drug controlled HIV.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.